US2018256759A1PendingUtilityA1

Dab-4 linked nitroxide citrate, useful as mri contrast agent

60
Assignee: NITROSCI PHARAMACEUTICALS INCPriority: Oct 23, 2012Filed: Mar 9, 2018Published: Sep 13, 2018
Est. expiryOct 23, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Gerald M. RosenErika Schneider
G01R 33/5601A61B 2576/02A61B 5/4514A61B 2503/08A61B 5/4576A61B 5/4585A61B 5/4528A61B 5/055A61K 49/20
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of imaging a joint of a subject comprises administering to the subject an amount of a salt of DAB-4 linked nitroxide citrate effective to enhance an MRI image of the joint and taking an MRI image of said joint.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . A compound comprising:
 DAB-4 linked nitroxide citrate.   
     
     
         14 . The compound of  claim 13  wherein the citrate salt is a 1:1 molar ratio citric acid:DAB-4 linked nitroxide. 
     
     
         15 . A pharmaceutical composition comprising the compound of  claim 13  and a pharmaceutically acceptable carrier. 
     
     
         16 . The pharmaceutical composition comprising the DAB-4 linked nitroxide citrate of  claim 14  and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2018256759A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.